Ciancio, A.; Ribaldone, D.G.; Spertino, M.; Risso, A.; Ferrarotti, D.; Caviglia, G.P.; Carucci, P.; Gaia, S.; Rolle, E.; Sacco, M.;
et al. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines 2023, 11, 166.
https://doi.org/10.3390/biomedicines11010166
AMA Style
Ciancio A, Ribaldone DG, Spertino M, Risso A, Ferrarotti D, Caviglia GP, Carucci P, Gaia S, Rolle E, Sacco M,
et al. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines. 2023; 11(1):166.
https://doi.org/10.3390/biomedicines11010166
Chicago/Turabian Style
Ciancio, Alessia, Davide Giuseppe Ribaldone, Matteo Spertino, Alessandra Risso, Debora Ferrarotti, Gian Paolo Caviglia, Patrizia Carucci, Silvia Gaia, Emanuela Rolle, Marco Sacco,
and et al. 2023. "Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study" Biomedicines 11, no. 1: 166.
https://doi.org/10.3390/biomedicines11010166
APA Style
Ciancio, A., Ribaldone, D. G., Spertino, M., Risso, A., Ferrarotti, D., Caviglia, G. P., Carucci, P., Gaia, S., Rolle, E., Sacco, M., & Saracco, G. M.
(2023). Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines, 11(1), 166.
https://doi.org/10.3390/biomedicines11010166
